Celsus Therapeutics PLC: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Celsus Therapeutics PLC announces the closing of $9.2 mln public offering and full exercise of underwriter's option to purchase additional ADSs
Celsus Therapeutics PLC:Says the closing of its previously announced public offering of 1,533,333 American Depository Shares on the NASDAQ Capital Market at a price of $6.00 per ADS. The final number of ADSs includes the full exercise by the underwriter of its option to purchase 200,000 additional ADSs.Each ADS represents ten of the company's ordinary shares.Says gross proceeds from this offering, including from the exercise of the over-allotment option, before underwriting discounts and commissions and other offering expenses, are expected to be about $9,200,000.The proceeds from the offering are to be used by Celsus to continue development of MRX-6 for atopic dermatitis, as well as further advancement of Celsus's pipeline programs, for further product development and for general corporate purposes.
Latest Developments for Celsus Therapeutics PLC
Latest Key Developments in Biotechnology
- Omeros Corporation announces positive OMS721 Data in Serum from patients with aHUS
- Amarantus BioScience Holdings Inc closes warrant solicitation and enters into $20 mln purchase agreement with Lincoln Park Capital Fund, LLC
- Neurovive Pharmaceutical to evaluate IPO of subsidiary in Taiwan
- Aviator resolves compulsory acquisition of Algeta
- Share this
- Digg this